PUBLIC COMPANY
saveREGENERON PHARMACEUTICALS
USupdated 5mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
- phase3REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
- phase2REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
- phase2REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
- phase3Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
- phase3A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- phase2Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
- phase1First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
🐶 Hiring Signal
News
- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingThe latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.biopharma_dive · 2d ago
- Pfizer’s eczema drug clears skin in mid-stage trialDetailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.biopharma_dive · 3d ago
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successorSanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…biospace · 3d ago
- STAT+: Sanofi, Regeneron expand partnership after Dupixent successSanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.stat · 4d ago
- Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&DSanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage immunology programs, teeing the longstanding partners up to try to replicate Dupixent’s success.fiercebiotech · 4d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 4d ago
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approvalA former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.biopharma_dive · 4d ago
- Kodiak skyrockets on positive study data for 2 eye drugsThe Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.biopharma_dive · 6d ago
- FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone diseaseThe approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regenero…biospace · 6d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 7d ago
comments(0)
5-min edit window · permanent after that